I-Mab Appoints Directors, Forms R&D Committee, and Appoints to Advisory Board

I-Mab has appointed Dr. Robert Lenz and Ms. Xin Liu to its Board of Directors, effective August 22, 2025. Dr. Sean Cao was previously appointed on May 28, 2025. Lielie Zhang will step down from the Board on August 20, 2025. The company has also established a Research and Development Committee to accelerate innovation and long-term growth. Dr. Ken Takeshita has been appointed to the Scientific Advisory Board.

I-Mab (NASDAQ:IMAB), a U.S.-based global biotech company focused on immuno-oncology, has announced significant leadership enhancements and strategic initiatives. The company has appointed Dr. Robert Lenz and Ms. Xin Liu to its Board of Directors, effective August 22, 2025, and previously appointed Dr. Sean Cao on May 28, 2025. Lielie Zhang will step down from the Board on August 20, 2025. Additionally, I-Mab has established a Research and Development Committee to accelerate innovation and long-term growth, and Dr. Ken Takeshita has been appointed to the Scientific Advisory Board [1].

Dr. Robert Lenz, a veteran research and development leader, brings extensive experience to the Board. He previously served as Executive Vice President and Head of Research and Development at Neumora Therapeutics, Inc., and held key leadership roles at Amgen Inc. and Abbott Laboratories. Ms. Xin Liu, an investment director at Hony Capital, adds finance and governance expertise to the Board, having previously served at CCBPE and the Fosun Group. Dr. Sean Cao, an accomplished biotech executive and entrepreneur, has founded and led multiple biotech companies, including Ensem Therapeutics, Inc., and Everest Medicines. Dr. Ken Takeshita, a recognized biopharmaceutical executive, brings clinical development expertise to the Scientific Advisory Board, having held senior R&D and global clinical leadership positions at various companies [1].

The appointment of these seasoned executives and the establishment of the R&D Committee reflect I-Mab’s commitment to advancing its precision immuno-oncology pipeline, particularly the givastomig program. Givastomig, a bispecific antibody designed to treat Claudin 18.2-positive gastric cancers, has shown promising results in Phase 1 trials, demonstrating strong tumor-binding and anti-tumor activity while minimizing toxicities [1].

I-Mab’s strategic initiatives, including the appointment of these executives and the formation of the R&D Committee, aim to drive innovation and long-term growth. The company’s focus on R&D excellence and strategic foresight is evident in these appointments, which are expected to support the clinical development and commercialization of its drug candidates [1].

References:
[1] https://www.stocktitan.net/news/IMAB/i-mab-announces-the-appointment-of-seasoned-biotech-executives-to-60b0iiqzwtz0.html